May 1, 2024
Medical Retina Articles
May 1, 2024
Upfront: The Technological Intersection of Aviation and Retina
By Peter K. Kaiser, MD
April 1, 2024
Upfront: Innovations in VEGF Inhibition Delivery
By Peter K. Kaiser, MD
April 1, 2024
Clinical Trial Update April 2024
April 1, 2024
New Product Applications: The First FDA-approved Topical Ocular Anesthetic Debuts
By Karen Appold, contributing writer
April 1, 2024
Improving Durability of Drugs in Wet AMD
By Lucas W. Rowe, MD, Thomas A. Ciulla, MD, MBA
April 1, 2024
Subspecialty News April 2024
By Rochelle Nataloni, contributing writer
April 1, 2024
Tyrosine Kinase Inhibitors for Wet AMD and Diabetic Retinopathy
By Nikhil Das, MD, Katherine E. Talcott, MD, FASRS
April 1, 2024
Nesvategrast Fails to Meet Primary Efficacy Endpoint in DR:EAM Trial
By Jim Gallagher, managing editor
April 1, 2024
Broader VEGF Pathway Inhibition for Wet AMD
By Mark R. Barakat, MD, Mark P. Breazzano, MD
January 1, 2024
Clinical Trial Update January/February 2024
January 1, 2024
CONTROVERSIES IN CARE: Withdrawal of Anti-VEGF Agents in Neovascular AMD
By Michael Colucciello, MD, Anat Loewenstein, MD, MHA, Diana V. Do, MD
November 1, 2023
NEW PRODUCT APPLICATIONS: Drug Slows the Progression of Geographic Atrophy
By Karen Appold, contributing writer
November 1, 2023
Clinical Trial Update November/December 2023
October 1, 2023
Clinical Trial Update October 2023
October 1, 2023
Clinical Pearls for Newly Approved Treatments for GA
By Aamir A. Aziz, BS, Carl Danzig, MD
September 1, 2023
Bispecific Antibodies in Retina Therapies
By René Rückert, MD, MBA, Gemmy Cheung Chui Ming, FRCOphth, Marion R. Munk, MD, PhD, FEBO
September 1, 2023
CODING Q&A: Medicare Reimbursement for Discarded Drugs
By Brandy H. Sperry, COMT, COE, OCS
September 1, 2023
Clinical Trial Update September 2023
July 1, 2023
Clinical Trial Update July/August 2023
April 1, 2023
Clinical Trial Update April 2023
February 1, 2023
SUBSPECIALTY NEWS: Methotrexate for vitreoretinal lymphoma, drugs for retinitis pigmentosa, AI technology in retina, and more.
By Rochelle Nataloni, contributing writer
July 1, 2022
The Impact of Pregnancy on Diabetic Retinopathy and Its Implications
By Kanika Seth, Matthew W. Russell, MD, Justin C. Muste, MD, et al.
July 1, 2022
Oral Drug Pipeline for Retinal Disease
By Charles DeBoer, MD, PhD, Suzanne Michalak, MD, Ehsan Rahimy, MD
July 1, 2022
Potential Implications of Silicone Oil From Syringes
By Gustavo B. Melo, MD, PhD, FASRS
July 1, 2022
UPFRONT: Retina Drug Shortages
By Peter K. Kaiser, MD
June 1, 2022
SUBSPECIALTY NEWS: Geographic atrophy quality-of-life survey, Xipere launch, ophthalmic bevacizumab FDA application, and more.
By Rochelle Nataloni, contributing writer
April 1, 2022
The Current Landscape of Intravitreal Treatments for Neovascular AMD
By Matias Iglicki, MD, Anat Loewenstein, MD, MHA, Dinah Zur, MD
April 1, 2022
UPFRONT: Medical Therapy in a Time of War
By Peter K. Kaiser, MD
April 1, 2022
SUBSPECIALTY NEWS: FDA approves uveal melanoma treatment, sepofarsen fails to meet endpoints, and more.
By Rochelle Nataloni, contributing writer
March 1, 2022
Intraocular Inflammation Associated With Current and Prospective Therapies for Patients With Wet AMD
By Andreas M. Wingert, Jayanth Sridhar, MD
February 1, 2022
Faricimab Approved by the FDA for Wet AMD and DME
By Rochelle Nataloni, contributing writer